Press release
Dilated Cardiomyopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Vericel Crp, AstraZeneca, Pfizer, Capricor Therapeutics, t2cure GmbH, Capricor Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dilated Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Dilated Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.The Dilated Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Dilated Cardiomyopathy Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dilated Cardiomyopathy Market.
Some of the key takeaways from the Dilated Cardiomyopathy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Dilated Cardiomyopathy treatment therapies with a considerable amount of success over the years.
*
Dilated Cardiomyopathy companies working in the treatment market are Constant Therapeutics LLC, Cumberland Pharmaceuticals, Solid Biosciences Inc., DiNAQOR, Heartseed, Bristol-Myers Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, and others, are developing therapies for the Dilated Cardiomyopathy treatment
*
Emerging Dilated Cardiomyopathy therapies in the different phases of clinical trials are- talfirastide, Ifetroban, AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803/ARRY-371797, MYK-491, CAP-1002, and others are expected to have a significant impact on the Dilated Cardiomyopathy market in the coming years.
*
In April 2022, The FDA has granted approval for Camzyos (mavacamten) capsules to address symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) in adults. This approval aims to enhance exercise capacity and alleviate associated symptoms.
*
In September 2022, Rocket Pharmaceuticals has acquired Renovacor in a strategic move to expand its position in AAV-based cardiac gene therapy, specifically targeting substantial unmet medical needs associated with BAG3-related dilated cardiomyopathy. This acquisition presents a notable commercial opportunity similar in scope to Danon Disease, further solidifying Rocket's leadership in this therapeutic domain.
*
In August 2020, Bristol-Myers Squibb has begun an open-label, exploratory investigation into the safety and early effectiveness of Danicamtiv among stable ambulatory patients diagnosed with primary dilated cardiomyopathy attributed to MYH7 or TTN variants.
Dilated Cardiomyopathy Overview
The most prevalent kind, dilated cardiomyopathy (DCM), primarily affects adults under 50. The bottom and upper chambers of the heart, the ventricles and atria, are the main areas affected. It is a non-ischaemic cardiac muscle disorder characterized by anomalies in the structure and function of the heart.
Get a Free Sample PDF Report to know more about Dilated Cardiomyopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dilated-cardiomyopathy-pipeline-insight [https://www.delveinsight.com/report-store/dilated-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Emerging Dilated Cardiomyopathy Drugs Under Different Phases of Clinical Development Include:
*
talfirastide: Constant Therapeutics LLC
*
Ifetroban: Cumberland Pharmaceuticals
*
AVB-401: Solid Biosciences Inc.
*
DINA-006: DiNAQOR
*
HS-001: Heartseed
*
Danicamtiv: Bristol-Myers Squibb
*
BC 007: Berlin Cures
*
PF-07265803/ARRY-371797: Pfizer
*
MYK-491: Bristol-Mayers Squibb
*
CAP-1002: Capricor Therapeutics
Dilated Cardiomyopathy Route of Administration
Dilated Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Intravenous
*
Subcutaneous
Dilated Cardiomyopathy Molecule Type
Dilated Cardiomyopathy Products have been categorized under various Molecule types, such as
*
Small molecule
*
Cell Therapy
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Dilated Cardiomyopathy Pipeline Therapeutics Assessment
*
Dilated Cardiomyopathy Assessment by Product Type
*
Dilated Cardiomyopathy By Stage and Product Type
*
Dilated Cardiomyopathy Assessment by Route of Administration
*
Dilated Cardiomyopathy By Stage and Route of Administration
*
Dilated Cardiomyopathy Assessment by Molecule Type
*
Dilated Cardiomyopathy by Stage and Molecule Type
DelveInsight's Dilated Cardiomyopathy Report covers around 10+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Dilated Cardiomyopathy product details are provided in the report. Download the Dilated Cardiomyopathy pipeline report to learn more about the emerging Dilated Cardiomyopathy therapies [https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key companies in the Dilated Cardiomyopathy Therapeutics Market include:
Key companies developing therapies for Dilated Cardiomyopathy are - Vericel Corporation, AstraZeneca plc., Pfizer Inc., Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc., t2cure GmbH, MyoKardia and Kasiak Research pvt.ltd., and others.
Dilated Cardiomyopathy Pipeline Analysis:
The Dilated Cardiomyopathy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Dilated Cardiomyopathy with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dilated Cardiomyopathy Treatment.
*
Dilated Cardiomyopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Dilated Cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dilated Cardiomyopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dilated Cardiomyopathy drugs and therapies [https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Dilated Cardiomyopathy Pipeline Market Drivers
*
Need of novel treatment, rising incidence of congestive heart failure are some of the important factors that are fueling the Dilated Cardiomyopathy Market.
Dilated Cardiomyopathy Pipeline Market Barriers
*
However, lack of pipeline therapies, several associated causes of Dilated Cardiomyopathy and other factors are creating obstacles in the Dilated Cardiomyopathy Market growth.
Scope of Dilated Cardiomyopathy Pipeline Drug Insight
*
Coverage: Global
*
Key Dilated Cardiomyopathy Companies: Constant Therapeutics LLC, Cumberland Pharmaceuticals, Solid Biosciences Inc., DiNAQOR, Heartseed, Bristol-Myers Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, and others
*
Key Dilated Cardiomyopathy Therapies: talfirastide, Ifetroban, AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803/ARRY-371797, MYK-491, CAP-1002, and others
*
Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and Dilated Cardiomyopathy emerging therapies
*
Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers
Request for Sample PDF Report for Dilated Cardiomyopathy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/dilated-cardiomyopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Dilated Cardiomyopathy Report Introduction
2. Dilated Cardiomyopathy Executive Summary
3. Dilated Cardiomyopathy Overview
4. Dilated Cardiomyopathy- Analytical Perspective In-depth Commercial Assessment
5. Dilated Cardiomyopathy Pipeline Therapeutics
6. Dilated Cardiomyopathy Late Stage Products (Phase II/III)
7. Dilated Cardiomyopathy Mid Stage Products (Phase II)
8. Dilated Cardiomyopathy Early Stage Products (Phase I)
9. Dilated Cardiomyopathy Preclinical Stage Products
10. Dilated Cardiomyopathy Therapeutics Assessment
11. Dilated Cardiomyopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dilated Cardiomyopathy Key Companies
14. Dilated Cardiomyopathy Key Products
15. Dilated Cardiomyopathy Unmet Needs
16 . Dilated Cardiomyopathy Market Drivers and Barriers
17. Dilated Cardiomyopathy Future Perspectives and Conclusion
18. Dilated Cardiomyopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dilated-cardiomyopathy-pipeline-analysis-2024-updates-latest-fda-ema-and-pmda-approvals-vericel-crp-astrazeneca-pfizer-capricor-therapeutics-t2cure-gmbh-capricor-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dilated Cardiomyopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Vericel Crp, AstraZeneca, Pfizer, Capricor Therapeutics, t2cure GmbH, Capricor Therapeutics here
News-ID: 3508932 • Views: …
More Releases from ABNewswire

Avanti Rides Debuts in Southern Florida, Transforming How Drivers and Passengers …
Miami, FL - Avanti Rides introduces a new chapter in ride-hailing by combining passenger safety, driver empowerment, and seamless technology into a single app. Designed for the evolving needs of both drivers and riders, Avanti is delivering smarter bookings, stronger protection, and unmatched flexibility.
Built for Drivers Who Want More Than Just Rides
Avanti Rides recognizes that drivers are the foundation of the platform and offers a range of benefits focused on…

UVS-IT Unveils Guide to Choosing the Best Managed IT Services in Atlanta
Hey there, Atlanta business warriors! Have you ever felt that picking the perfect Managed IT Service is a bit like choosing the ultimate wingman for your company's tech needs? Trust me, it's not just a matter of finding someone who looks good on paper. With technology increasingly steering the ship of our businesses, selecting a reliable Managed IT Service is becoming as crucial as that morning cup of coffee we…

3D-Engineering: How 3D Scanning Services Are Revolutionizing Modern Engineering …
Imagine being able to capture every nook and cranny of an object down to the most intricate detail. Sounds magical, right? That's the power of 3D scanning services [https://3d-engineering.net/engineering-services/3d-laser-scanning-services/] in today's engineering projects. Across industries, from automotive and construction to aerospace and healthcare, 3D scanning is transforming how things are measured, mapped, and made. Whether you're designing a new building or manufacturing precision components, 3D scanning takes you from the…

SLCLawyer: How a Separation Agreement Can Help Couples Save Thousands in Legal F …
Image: https://www.abnewswire.com/upload/2025/10/7d762be2535d9a3c2274975ea0a87869.jpg
When John and Mary decided to separate after 12 years of marriage, they thought they could handle it on their own. Money was tight, emotions were high, and the internet offered dozens of free and cheap separation agreement templates. They downloaded one, filled in the blanks, and signed it at the kitchen table.
At first, it seemed like a practical solution. They avoided paying lawyers, saved a few hundred dollars,…
More Releases for Dilated
Dilated Cardiomyopathy Market Forecast: Trends and Analysis 2024-2031
The "Dilated Cardiomyopathy Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Dilated Cardiomyopathy Market - Rebuilding Hope, Restoring Hearts: Dilated Cardi …
Newark, New Castle, USA: The "Dilated Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Dilated Cardiomyopathy Market: https://www.growthplusreports.com/report/dilated-cardiomyopathy-market/7764
This latest report researches the industry structure, sales, revenue,…
Dilated Cardiomyopathy Market Report, History and Forecast 2022-2030
Dilated Cardiomyopathy Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dilated Cardiomyopathy industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Global Dilated Cardiomyopathy Market Insights, Forecast
Dilated Cardiomyopathy (DCM) refers to the cardiac hypertrophy, cannot effectively pump blood. Dilated Cardiomyopathy (DCM) is due to genetic or other disease caused by a heart disease, it respectively affect the ventricles of the heart and heart, the inferior vena chamber and the upper Chambers of the heart. The global Dilated Cardiomyopathy market is valued at 180 million US$ in 2018 and will reach 290 million US$ by the end…
Dilated Cardiomyopathy Market Opportunity Analysis, 2026 – 2026
Dilated cardiomyopathy (DCM) is a condition in which the heart gets enlarged and is not able to efficiently pump blood. The reduced heart function can affect the functioning of other organs such as lungs, liver, and kidney. The heart muscles begin to dilate (stretches), which result in thinning and increased area of the chamber, further it spreads to the right ventricle and atria’s. As the heart chambers dilate, heart muscles…
Dilated Cardiomyopathy Therapeutics Market Research Report Forecast
A new market research report has been recently published by Transparency market research, a leading market intelligence firm. The research report, titled “Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020”, presents a market overview, market drivers, opportunities, challenges, product segmentation, and competitive landscape. The research report also features inputs and recommendations from industry experts and professionals to help the…